Consultants for WHO’s SECURE, Wellcome-ICARS-Danish Gov’t AMR event

Dear All, See below my signature:

  • A 6-month consultancy with WHO to support the the SECURE initiative, a program to assist countries in accessing and sustainably managing new and existing antibiotics needed to cope with antimicrobial resistance (AMR). There’s not much online (yet) about SECURE: the best description I can find is in the Terms of Reference for the consultancyDeadline: 6 Aug 2021
  • A 4-month consultancy to support Wellcome Trust, the Danish Government, and the International Centre for AMR Solutions (ICARS) in holding a third Call to Action on Antimicrobial Resistance (AMR) virtual event in November 2021. Previous Call to Action events were in Berlin and Ghana; this 3rd event will be virtual and will have a focus on Asia and Latin America. Deadline: 25 July 2021

Perhaps one of these is for you! All best wishes, –jr

John H. Rex, MD | Chief Medical Officer, F2G Ltd. | Operating Partner, Advent Life Sciences. Follow me on Twitter: @JohnRex_NewAbx. See past newsletters and subscribe for the future: All opinions are my own.

— WHO consultancy —
The World Health Organization’s (WHO) GCP Department – in collaboration with other partners (GARDP, UNICEF, CHAI) – is developing a novel access initiative, named SECURE. SECURE will support countries in accessing and sustainably managing new and existing antibiotics to manage antimicrobial resistance (AMR).
Time: September 2021-February 2022 (6 months full-time)
Location: Anywhere
Experience: 5+ years of professional experience in access to medicines, AMR and/or the set-up of new global health initiatives (minimal, more experienced candidates welcome to apply: pay rate based on experience)

Questions? Reach out on:

— Wellcome-ICARS-Danish Government consultancy —
Wellcome Trust, the Danish Government and the International Centre for AMR Solutions (ICARS), working with fellow co-hosts, are looking to hold a third Call to Action on Antimicrobial Resistance (AMR) virtual event in November 2021.
As a result, we want to engage one or two individuals with experience of working with/within LMIC governments in Asia and/or Latin America developing and implementing AMR National Action Plans (NAPs) to play a strategic role supporting the development (inc. associated content) and delivery of the third Call to Action event alongside the event co-hosts. This role will be part of a team and will complement expertise coming from other territories.
Responsibilities would include:

  • working as a member of the agenda delivery team to shape the session content for the event. Using your own experience, expertise, and networks to bring this together with the event co-hosts and other stakeholders to design the agenda, taking a solution focused approach.
  • lead or co-lead on the development and delivery of specific sessions of the agenda (details will be determined once the outline agenda has been agreed), using your experience of NAP implementation and networks of AMR policy experts, collaborating with event co-hosts and relevant stakeholders.
  • supporting delivery of the event over the conference dates, e.g. briefing/supporting speakers, moderating small group discussions.

It is expected that the role will run from August to end of November and that each consultant will allocate 20-25 hours per month. 
How to apply:
Please submit a one-page expression of interest, along with a CV (no more than 2pgs) which sets out how you meet the desired skills/experiences. In this document, please provide one or two examples of work that you have done to support the implementation of AMR national action plans. Please highlight how you personally contributed to deliver of the activity and the insights this provided. 
Applications should be emailed to Ghada Zoubiane ( by not later than CoP 25th July 2021.
Short-listed applications will be invited for a short online interview currently planned on 2nd and 3rd of August 2021 to discuss experience and skills.
For more information please visit:

Current funding opportunities (most current list is here):

  • CARB-X recently announced that their existing resources will be reserved to fund their existing portfolio (more than 80 total awards, and counting, as they include contracting from prior rounds). New rounds from CARB-X will occur only after new funding is obtained in 2021.
  • It’s not a funder, but AiCuris’ AiCubator offers incubator support to very early stage projects. Read more about it here.
  • The Global AMR R&D Hub’s dynamic dashboard (link) summarizes the global clinical development pipeline, incentives for AMR R&D, and investors/investments in AMR R&D.
  • In addition to the lists provided by the Global AMR R&D Hub, you might also be interested in my most current lists of R&D incentives (link) and priority pathogens (link).

Upcoming meetings of interest to the AMR community (most current list is here):

  • 20 Jul 2021 (virtual, 16.30-18.00 BST): BSAC-sponsored webinar entitled “Diagnostic-driven strategies for antimicrobial resistance in the UK” that will highlight AMR priorities and diagnostic needs for the UK’s NHS. Go here to register.
  • 26 Jul-30 Jul 2021 (online): Small World Initiative Instructor Training Workshop – training for undergraduate professors in the wet lab techniques, parallel curricula, & pedagogical instruction to engage students in the hunt to find new antibiotic-producing soil microbes. Go here to register.
  • 27 Jul 2021 (virtual, 5-6.30p CEST / 11a-12.30p EDT): GARDP-sponsored webinar entitled “Discovering and developing new treatments for fungal infections.” Go here to register.
  • 14-29 Aug 2021 (Marine Biology Laboratory, Woods Hole, MA): Residential course entitled “Molecular Mycology: Current Approaches to Fungal Pathogenesis.” This 2-week intensive training program has run annually for many years and gets outstanding reviews. Go here for details.
  • 24-26 Aug 2021 (virtual, timings not stated but presumably EU-centered): The 5th edition of the annual AMR conference sponsored by the BEAM Alliance, CARB-X, the Novo REPAIR Impact Fund, the IMI Accelerator, and the European Biotechnology Network. The in-person version of this meeting is consistently excellent; the video-based version will have to do for 2021. Go here for details. 
  • 8-11 Oct 2021 (Aberdeen, Scotland): 10th Trends in Medical Mycology. Go here for details.
  • 11-15 Oct 2021 (physical, somewhere in the UK): UK-focused Innovation Mission sponsored by Innovate UK in collaboration with AMR Insights and Oxford innovation. This free event seeks to connect AMR-focused start-ups, SMEs and Multinationals, Academia, Research Institutes, Regional Development Companies and other interested stakeholders in the UK, Europe and other parts of the world. Go here for more details.
  • 16-24 Oct 2021 (Annecy, France): Interdisciplinary Course on Antibiotics and Resistance (ICARe). This is a soup-to-nuts residential course on antibiotics, antibiotic resistance, and antibiotic R&D. The course is very intense, very detailed, and gets rave reviews. Registration is here and is limited to 40 students. Bonus feature: For obvious reasons, the course didn’t happen in 2020! But as a celebration of the course’s 5th year, a webinar version was held on 29 Oct 2020: go here to stream it. 
  • 5-8 Nov 2021 (Albuquerque, New Mexico): Biannual meeting of the MSGERC (Mycoses Study Group Education and Research Consortium). Save-the-date announcement is here, details to follow.
  • 6-11 Mar 2022 (Il Ciocco, Tuscany): Gordon Research Conference entitled “New Antibacterial Discovery and Development”. Go here for details, go here for the linked 5-6 Mar Gordon Research Seminar that precedes it.
  • 25-28 Oct 2022 (Stellenbosch, South Africa): The University of Cape Town’s H3D Research Centre will celebrate its 10th anniversary with a symposium covering the Centre’s research on Malaria, TB, Neglected Tropical Diseases, and AMR. Go here to register.


ENABLE-2 funding now includes Hit Identification & Validation

Dear All, I wrote on 25 Aug 2023 about the ENABLE-2 program and its support for hit-to-lead compound development. As a reminder, that program is focused on molecules with the potential to be direct-acting therapies for one or more of the following priority pathogens: ESBL-producing/carbapenem-resistant Enterobacteriaceae (E. coli, K. pneumoniae), P. aeruginosa, A. baumannii, methicillin-resistant S. aureus, or vancomycin-resistant E. faecium. Adding to that program, there is now an ENABLE-2

NIAID/DMID thinking for FY2026: Antibacterials, Phage, and Antifungals

Dear All, NIAID’s DMID (Division of Microbiology and Infectious Diseases) recently held a council meeting during which they proposed program concepts that encompassed both antibacterial therapies (including phage) as well as antifungal therapies for funding in FY 2026 (the year that would run from 1 Oct 2025 to 30 Sep 2026). There is no guarantee that

WHO Antibacterial Pipeline Review: Update thru 31 Dec 2023

Dear All, WHO have released an update through 31 Dec 2023 of their ongoing series of antibacterial pipeline reviews! Here are the links you need: The report: 2023 Antibacterial agents in clinical and preclinical development: an overview and analysis and a press release about the report. Infographics: Key facts and recommendations from the 2023 antibacterial agents in clinical

The (confusing!) language of AMR: ChatGPT tries to help!

Dear All (Wonkish alert! Not technical but lengthy … so settle in and enjoy the ride!): Regular readers will know of my fascination with language: e.g., this 20 Feb 2020 newsletter entitled “Language Matters: CRE vs. CPE; SDD vs. I; And MDR, XDR, PDR, UDR vs. DTR.” How about that for acronymics taken to Olympian

Scroll to Top